ArticleAnalytical chemistry2025
Development of a Highly Multiplexed RT-LAMP Assay for Coverage of Genetic Sequence Diversity.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Nucleic acid amplification tests (NAATs) can achieve high accuracy for diagnosing infectious diseases by targeting conserved genetic sequences specific to the target organism. Isothermal NAATs, such as reverse-transcription loop mediated isothermal amplification (RT-LAMP), simplify instrumentation requirements, facilitating point-of-care testing. However, sequence variation due to genetic variability can cause false negative results. Single-pot multiplex testing can improve sequence coverage, but RT-LAMP is complicated by requiring many primers for even a single assay, which can lead to nonspecific amplification. We implemented a process that leveraged manual primer design to develop a highly multiplexed RT-LAMP assay (Chain LAMP) targeting 7 adjacent genomic target regions of HIV, one of the most diverse clinically relevant pathogens. This process departed from standards for RT-LAMP design, including the omission of bumper primers whose activity was replaced by cooperative neighboring assays. The Chain LAMP is, to our knowledge, the highest order single-pot multiplexed RT-LAMP assay published. The assay has an analytical limit of detection of 25 copies of RNA/reaction without detectable nonspecific amplification, translating to 1000 copies of HIV/mL of plasma from a fingerstick sample, aligning with WHO standards for HIV viral load monitoring. When evaluated using 24 clinical RNA samples representative of global HIV diversity, Chain LAMP demonstrated robust coverage of sequence diversity, amplifying all samples with minimal sensitivity variation. We performed mechanistic analysis with Nanopore sequencing, identifying liftoff of multiple assay regions for each sample, indicating many initiation loci. The high level of multiplexing in the Chain LAMP effectively increases the coverage of HIV sequence diversity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.